Evidence map›Paper›PMID 36064752›Full record

ArticleBone marrow transplantation2022

Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant.

Chikara Ogimi, Elizabeth M Krantz, Jonathan L Golob, Catherine Liu, Alpana Waghmare, Ashley Akramoff, Anthony Mallory, Wendy M Leisenring, Keith R Jerome, Victor A Chow and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Chikara Ogimi *Pediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA. ogimi-c@ncchd.go.jp.ORCID 0000-0002-2166-8152
Elizabeth M Krantz *Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jonathan L GolobVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Catherine LiuDepartment of Pediatrics, University of Washington, Seattle, WA, USA.ORCID 0000-0002-7532-4822
Alpana WaghmarePediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA.ORCID 0000-0003-2268-9470
Ashley AkramoffPediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA.
Anthony MalloryPediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA.
Wendy M LeisenringClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0001-7405-0906
Keith R JeromeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-8212-3789
Victor A ChowClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Steven A PergamVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
David N FredricksVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Janet A EnglundPediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA.
Michael BoeckhVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. mboeckh@fredhutch.org.
Seattle Children's Hospital · USUniversity of Washington · USFred Hutch Cancer Center · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAUniversity of Washington Medical Center · US

Funding

VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
Respiratory Viruses and Airflow Obstruction after HCTR01HL081595 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2005 to 2008
$2.5M
Infections in Hematopoietic Cell Transplant RecipientsK24HL093294 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2009 to 2019
$1.5M
Impact of Cumulative Exposure to Respiratory Viruses after Allogeneic Hematopoietic Cell TransplantationK23AI139385 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI OGIMI, CHIKARA · 2019 to 2021
$557k
NCI NIH HHS P01 CA018029NHLBI NIH HHS K24 HL093294NHLBI NIH HHS R01 HL081595NIAID NIH HHS K23 AI139385
6 · The paper itself

Abstract

We examined associations between specific antibiotic exposures and progression to lower respiratory tract disease (LRTD) following individual respiratory viral infections (RVIs) after hematopoietic cell transplantation (HCT). We analyzed allogeneic HCT recipients of all ages with their first RVI during the first 100 days post-HCT. For the 21 days before RVI onset, we recorded any receipt of specific groups of antibiotics, and the cumulative sum of the number of antibiotics received for each day (antibiotic-days). We used Cox proportional hazards models to assess the relationship between antibiotic exposure and progression to LRTD. Among 469 patients with RVI, 124 progressed to LRTD. Compared to no antibiotics, use of antibiotics with broad anaerobic activity in the prior 21 days was associated with progression to LRTD after adjusting for age, virus type, hypoalbuminemia, neutropenia, steroid use, and monocytopenia (HR 2.2, 95% CI 1.1-4.1). Greater use of those antibiotics (≥7 antibiotic days) was also associated with LRTD in adjusted models (HR 2.2, 95% CI 1.1-4.3). Results were similar after adjusting for lymphopenia instead of monocytopenia. Antibiotic use is associated with LRTD after RVI across different viruses in HCT recipients. Prospective studies using anaerobe-sparing antibiotics should be explored to assess impact on LRTD in patients undergoing HCT.

Indexed as

Hematopoietic Stem Cell TransplantationRespiratory Tract InfectionsVirus DiseasesAnaerobiosisAnti-Bacterial AgentsDisease ProgressionHumansInfantProspective StudiesRetrospective StudiesAnti-Bacterial Agents

Identifiers

PMID36064752
OpenAlexW4294678668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.